PL3532457T3 - Postacie krystaliczne hydroksynorketaminy - Google Patents
Postacie krystaliczne hydroksynorketaminyInfo
- Publication number
- PL3532457T3 PL3532457T3 PL18758671T PL18758671T PL3532457T3 PL 3532457 T3 PL3532457 T3 PL 3532457T3 PL 18758671 T PL18758671 T PL 18758671T PL 18758671 T PL18758671 T PL 18758671T PL 3532457 T3 PL3532457 T3 PL 3532457T3
- Authority
- PL
- Poland
- Prior art keywords
- hydroxynorketamine
- crystalline forms
- crystalline
- forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/44—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton bound to carbon atoms of the same ring or condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1712304.3A GB201712304D0 (en) | 2017-07-31 | 2017-07-31 | Synthetic methods |
GBGB1715010.3A GB201715010D0 (en) | 2017-09-18 | 2017-09-18 | Crystalline forms |
GBGB1715500.3A GB201715500D0 (en) | 2017-09-25 | 2017-09-25 | Crystal forms of therapeutic compounds and dosage forms thereof |
EP18758671.4A EP3532457B1 (en) | 2017-07-31 | 2018-07-31 | Crystalline forms of hydroxynorketamine |
PCT/GB2018/052193 WO2019025792A1 (en) | 2017-07-31 | 2018-07-31 | CRYSTALLINE FORMS OF HYDROXYNORKETAMINE |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3532457T3 true PL3532457T3 (pl) | 2020-10-19 |
Family
ID=63294366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL18758671T PL3532457T3 (pl) | 2017-07-31 | 2018-07-31 | Postacie krystaliczne hydroksynorketaminy |
Country Status (9)
Country | Link |
---|---|
US (2) | US11377416B2 (pl) |
EP (1) | EP3532457B1 (pl) |
JP (1) | JP2020529445A (pl) |
CN (1) | CN111201217A (pl) |
AU (1) | AU2018311307B9 (pl) |
CA (1) | CA3071491A1 (pl) |
ES (1) | ES2797381T3 (pl) |
PL (1) | PL3532457T3 (pl) |
WO (1) | WO2019025792A1 (pl) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110343050B (zh) * | 2018-04-04 | 2021-09-24 | 上海键合医药科技有限公司 | 芳香类化合物及其制备方法和用途 |
US20230022767A1 (en) * | 2019-11-18 | 2023-01-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Salts of (2r, 6r)-hydroxynorketamine, their crystal forms, and methods of making the same |
US20230331655A1 (en) * | 2020-08-27 | 2023-10-19 | University Of Maryland, Baltimore | Hydroxynorketamine compounds and methods of use thereof |
CN112521357B (zh) * | 2020-08-31 | 2021-10-08 | 深圳瑞健生物科技有限公司 | 一种长效低成瘾性hnk衍生物及其制备方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817699A (en) | 1997-05-30 | 1998-10-06 | Flores; John A. | Process for the preparation of ketamine ointment |
KR100467669B1 (ko) * | 2002-08-21 | 2005-01-24 | 씨제이 주식회사 | 암로디핀의 유기산염 |
CN104395283A (zh) | 2011-10-14 | 2015-03-04 | 美国政府健康及人类服务部 | (2r,6r)-羟基去甲氯胺酮、(s)-脱氢去甲氯胺酮以及(r,s)-氯胺酮的其他立体异构脱氢和羟基化代谢物在治疗忧郁症和神经性疼痛中的应用 |
US20140079740A1 (en) | 2012-08-02 | 2014-03-20 | ClinPharm Support GmbH | Oral transmucosal adminstration forms of s-ketamine |
WO2014117089A1 (en) | 2013-01-25 | 2014-07-31 | Case Western Reserve University | Compositions and methods for the treatment of pervasive development disorders |
CA2936809A1 (en) | 2014-01-14 | 2015-07-23 | Children's Hospital Medical Center | Compositions comprising ketamine for treating an autism spectrum disorder |
CN115521217A (zh) | 2014-11-04 | 2022-12-27 | 阿莫萨治疗公司 | 神经衰减性氯胺酮和去甲氯胺酮化合物、其衍生物和方法 |
JO3456B1 (ar) * | 2015-05-13 | 2020-07-05 | H Lundbeck As | فيروتيوكسيتين بيروجلوتامات |
WO2016186968A1 (en) | 2015-05-15 | 2016-11-24 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating motor disorders |
EP3377050A4 (en) | 2015-11-17 | 2019-11-20 | The Trustees of Columbia University in the City of New York | PHARMACOLOGICAL PROPHYLACTIC AGENTS AGAINST STRESS INDUCED DISORDERS AND ASSOCIATED SYMPTOMS |
WO2017087388A1 (en) | 2015-11-18 | 2017-05-26 | Mitchell Woods Pharmaceuticals, Inc. | Phenyl cyclohexanone derivatives and methods of making and using them |
AU2017250086A1 (en) | 2016-04-11 | 2018-09-20 | Clexio Biosciences Ltd. | Deuterated ketamine derivatives |
EP3970712A3 (en) | 2016-06-03 | 2022-03-30 | Small Pharma Ltd | Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof |
CN110035997A (zh) | 2016-09-16 | 2019-07-19 | 生物制药沃克斯有限公司 | 羟基去甲氯胺酮前药 |
JPWO2018079693A1 (ja) | 2016-10-27 | 2019-10-31 | 国立大学法人千葉大学 | (s)−ノルケタミンおよびその塩の医薬品としての応用 |
WO2018102488A1 (en) * | 2016-11-30 | 2018-06-07 | Wolfson Philip E | Ketamine for the treatment of menstrually related symptoms |
EP3687515B1 (en) | 2017-09-25 | 2022-07-06 | Small Pharma Ltd | Solid oral dosage forms of ketamine derivatives |
-
2018
- 2018-07-31 PL PL18758671T patent/PL3532457T3/pl unknown
- 2018-07-31 CA CA3071491A patent/CA3071491A1/en active Pending
- 2018-07-31 ES ES18758671T patent/ES2797381T3/es active Active
- 2018-07-31 AU AU2018311307A patent/AU2018311307B9/en active Active
- 2018-07-31 CN CN201880063777.9A patent/CN111201217A/zh active Pending
- 2018-07-31 WO PCT/GB2018/052193 patent/WO2019025792A1/en unknown
- 2018-07-31 EP EP18758671.4A patent/EP3532457B1/en active Active
- 2018-07-31 JP JP2020506258A patent/JP2020529445A/ja active Pending
- 2018-07-31 US US16/635,406 patent/US11377416B2/en active Active
-
2022
- 2022-05-27 US US17/804,338 patent/US20220306569A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11377416B2 (en) | 2022-07-05 |
US20220306569A1 (en) | 2022-09-29 |
EP3532457B1 (en) | 2020-03-18 |
US20200157040A1 (en) | 2020-05-21 |
CN111201217A (zh) | 2020-05-26 |
WO2019025792A1 (en) | 2019-02-07 |
AU2018311307B9 (en) | 2021-09-09 |
AU2018311307B2 (en) | 2021-08-12 |
ES2797381T3 (es) | 2020-12-02 |
EP3532457A1 (en) | 2019-09-04 |
JP2020529445A (ja) | 2020-10-08 |
AU2018311307A1 (en) | 2020-02-13 |
CA3071491A1 (en) | 2019-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273730A (en) | crystalline forms | |
IL268852A (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitantane | |
HK1252845A1 (zh) | 勞拉替尼游離碱的結晶形式 | |
EP3136857A4 (en) | Crystalline form of baricitinib | |
IL246385A0 (en) | Crystalline forms of efitinib di-malate | |
IL269409A (en) | Combinations of chk1- and wee1 - inhibitors | |
SI3380554T1 (sl) | Kristalne oblike per-kloro-gama-ciklodekstrinov | |
HK1244274A1 (zh) | C21h22ci2n4o2的晶型 | |
HK1255112A1 (zh) | 吉西他濱的晶型 | |
PL3532457T3 (pl) | Postacie krystaliczne hydroksynorketaminy | |
IL253479A0 (en) | Crystalline forms of efinconazole | |
PT3113773T (pt) | Formas cristalinas do grapiprant | |
IL265445A (en) | crystalline forms | |
IL270961A (en) | Crystalline form of N-butyldeoxygalactonogirimycin | |
IL269792B (en) | Crystalline forms of (s)–apoxolner | |
IL269073A (en) | Crystalline forms of obeticholic acid | |
HK1255148A1 (zh) | 結晶形式 | |
GB201518589D0 (en) | Crystalline form of tetraacetylethylenediamine | |
IL270937A (en) | Crystalline forms of saltalicib | |
ZA201902553B (en) | Crystalline forms | |
GB201715010D0 (en) | Crystalline forms | |
IL261795A (en) | Crystalline form | |
GB201721386D0 (en) | Chrondogy of time-wave | |
GB201704789D0 (en) | Crystalline compounds |